United States pre-exposure prophylaxis (PrEP) market is bound to experience impressive growth with anticipated CAGR in the forecast period, 2022-2026, on the account of increasing instances of human immunodeficiency viral infection among the young adult and adult population of the country. Promoting the concept of prevention better than cure, pre-exposure drugs against viral infection drugs are popularized and thus driving the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years.

Pre-exposure prophylaxis (PrEP) drugs are a means of HIV prevention in which people who have risk of exposure to the infection in near future or may have contracted the viral infection in recent past as much as 6 months. Pre-exposure prophylaxis (PrEP) drugs have the ability to control the infection spread by human immunodeficiency virus.

These drugs are completely different from the HIV drugs that are given to the HIV positive patients. The are precautionary drugs given to the HIV negative adults and young adults that are at higher risk of HIV contraction while having sexual interactions with HIV positive patients, partners. Or through injection usage for drug administration.

Increased Awareness Drives Market Growth

Increasing awareness among the population of the country regarding PrEP drugs mostly among the male population having sex with same sex partner is driving the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years. According to the recent reports from Center of Disease Control (CDC) almost 95% of the US population is now well aware of the pre-exposure prophylaxis (PrEP) drugs and their advantages.

Governmental initiatives and private schemes are advancing the awareness about the HIV virus, preventions, precautions, treatment, and pre-treatment therapeutics like pre-exposure prophylaxis PrEP drugs also support the growth of the United States pre-exposure prophylaxis (PrEP) market in the future five years.

Social medial marketing campaigns like Act Against AIDS were a huge success in the past and similar schemes are also employed in future years. The country registers higher percentage of black and Hispanic population involved in MSM (men having sexual intercourse with another man or multiple men) kind of relationship and thus creates special evidence based approaches to educate the population regarding HIV infection and PrEP drugs for the prevention of the same.

HIV’s Decreasing Mortality Rate Drives Market Growth

Availability of the pre-exposure prophylaxis (PrEP) drugs and its awareness among the MSM population has established its advantage as an antiviral drug used to prevent prospective HIV infection. Acceptance of these drugs have decreased mortality rate among the US population significantly. In the reports KFF, a non-profit organization confirms that the United States registered 36.6% drop in the mortality rate where HIV was an underlying cause of death.

These have created affirmation among the population and promotes the uses of the pre-exposure prophylaxis (PrEP) drugs and thus supports the growth of the United States pre-exposure prophylaxis (PrEP) market in the next five years. Although, more than 5000 lives were claimed by HIV/AIDS as the underlying cause in the country in year 2019, using the pre-exposure prophylaxis (PrEP) drugs promises better future.

Changing Dating Pattern Increases PrEP Demands

Rapidly evolving dating pattern, online dating platforms, and increasing popularity of such platforms among the young population of the country is further increasing the demand for pre-exposure prophylaxis (PrEP) drugs and thus supports the growth of the United States pre-exposure prophylaxis (PrEP) market in the next five years.

In their research paper, Lauren Bineau, mentions that among their survey respondents, one-third of 74% dating app user knew and understood the administration of pre-exposure prophylaxis (PrEP) drugs. Thus, increasing the information spread and guidelines from the online platforms are further aiding the growth of the United States pre-exposure prophylaxis (PrEP) market in the future five years.


Click here to download the sample

Market Segmentation

The United States pre-exposure prophylaxis (PrEP) market segmentation is based on drug type, route of administration, competitional landscape, and regional distribution. Based on drug type, the market is further bifurcated into Truvada and Descovy. On the basis of route of administration, the market segments are defined as oral, and topical. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among South West region, Mid West region, and North East region.

Company Profile

Gilead Sciences, Inc., Teva Pharmaceuticals USA, Inc., Merck & Co., Inc., Cipla Inc, Bristol-Myers Squibb Company, Genentech, Inc., among others is a partial list of major market players of the companies responsible for the growth of United States pre-exposure prophylaxis (PrEP) market.

Attribute

Details

Base Year

2020

Historical Data

2016 – 2019

Estimated Year

2021

Forecast Period

2022 – 2026

Quantitative Units

Revenue in USD Million, and CAGR for 2016-2020 and 2021-2026

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

  • Drug Type
  • Route of Administration

Regional scope

South West, Mid West, North East

Key companies profiled

Gilead Sciences, Inc., Teva Pharmaceuticals USA, Inc., Merck & Co., Inc., Cipla Inc, Bristol-Myers Squibb Company, Genentech, Inc.,

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, United States pre-exposure prophylaxis (PrEP) market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • United States Pre-exposure prophylaxis (PrEP) Market, By Drug Type:

o   Truvada

o   Descovy

  • United States Pre-exposure prophylaxis (PrEP) Market, By Route of Administration:
    • Oral
    • Topical
  • United States Pre-exposure prophylaxis (PrEP) Market, By Region:
    • South West
    • Mid West
    • North East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States pre-exposure prophylaxis (PrEP) market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
United States Pre-Exposure Prophylaxis (PrEP) Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on United States Pre-Exposure Prophylaxis (PrEP) Market

4.    Voice of Customer

5.    Executive Summary

6.    United States Pre-Exposure Prophylaxis (PrEP) Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value & Volume

6.2.  Market Share & Forecast

6.2.1.     By Drug Type (Truvada v/s Descovy)

6.2.2.     By Route of Administration (Oral v/s Topical)

6.2.3.     By Company (2020)

6.2.4.     By Region

6.3.  Product Market Map

7.    North-East Pre-Exposure Prophylaxis (PrEP) Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug Type

7.2.2.     By Route of Administration

8.    Mid-West Pre-Exposure Prophylaxis (PrEP) Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug Type

8.2.2.     By Route of Administration

9.    West Pre-Exposure Prophylaxis (PrEP) Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drug Type

9.2.2.     By Route of Administration

10.  South Pre-Exposure Prophylaxis (PrEP) Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Drug Type

10.2.2.  By Route of Administration

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

13.  Policy & Regulatory Landscape

14.  United States Economic Profile

15.  Competitive Landscape

15.1.              Competition Outlook

15.2.              Company Profiles

15.2.1.  Gilead Sciences, Inc.

15.2.2.  Teva Pharmaceuticals USA, Inc.

15.2.3.  Merck & Co., Inc.

15.2.4.  Cipla Inc

15.2.5.  Bristol-Myers Squibb Company

15.2.6.  Genentech, Inc

16.  Strategic Recommendations

17.   About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]